EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Silvio Danese  ¹     Axel Dignass  ²     Katsuyoshi Matsuoka  ³     Marc Ferrante  ⁴     Millie Long  ⁵     Isabel Redondo  ⁶     Theresa Hunter Gibble  ⁶     Richard Moses  ⁶     Nathan Morris  ⁶     Xingyuan Li  ⁶     Catherine Milch  ⁶     Maria T. Abreu  ^7    
1 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
² Agaplesion Markus Krankenhaus, Frankfurt/ Main, Germany
³ Tokyo Medical and Dental University, Tokyo, Japan
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ University of North Carolina at Chapel hill, Chapel Hill, United States
⁶ Eli Lilly and Company, Indianapolis, United States
⁷ University of Miami, Miller School of Medicine, Miami, United States

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in ulcerative colitis I

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)